Piperidine Derivatives for CCR3 Receptor Selectivity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pharmaceutical agents for treating allergic disorders and inflammatory diseases, such as asthma, have limitations in potency and selectivity, leading to side effects and reduced efficacy, particularly in targeting chemokine receptors like CCR3 and histamine receptors.
Innovation Solution
Development of piperidine derivatives with specific structural modifications, such as (2S)-2-[4-[[4-(3,4-dichloro-2-methyl-phenoxy)-1-piperidyl]methyl]-1-piperidyl]-3-phenylpropanoic acid and its salts, which exhibit higher potency and selectivity for CCR3 receptors, reducing side effects and improving therapeutic outcomes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current pharmaceutical agents are used to treat allergic disorders and inflammatory diseases, then they can provide basic therapeutic coverage, but they exhibit limited potency and selectivity leading to side effects and reduced efficacy
Solution Approach 1:
The patent applies local quality by introducing specific substituent groups (R1-R6) at particular positions on the piperidine ring structure. Each substituent is strategically placed to enhance binding affinity to CCR3 receptors while maintaining selectivity, thereby improving therapeutic efficacy without proportionally increasing side effects.
Solution Approach 2:
The patent employs parameter changes by systematically varying chemical parameters including substituent types (halogens, alkyl groups, aryl groups), their positions on the piperidine ring, and stereochemical configurations. These parameter modifications optimize the balance between potency at CCR3 receptors and selectivity to minimize off-target effects.
2Reliability
If current pharmaceutical agents are used, then they can treat allergic disorders, but they show reduced selectivity over histamine type 1 receptors
Solution Approach 1:
The patent applies segmentation by dividing the pharmacological activity into distinct functional components: the piperidine core provides CCR3 selectivity while specific substituent patterns (R1-R6) modulate histamine H1 receptor interaction. This segmentation allows independent optimization of CCR3 binding affinity and H1 selectivity profiles.
Solution Approach 2:
The patent achieves universality by designing a multi-functional piperidine derivative that simultaneously targets multiple receptors (CCR3 and histamine H1) with appropriate selectivity. The molecule performs multiple therapeutic functions including chemokine receptor modulation and histamine antagonism, providing broad-spectrum activity against allergic and inflammatory conditions.
Data Source
Figure 1~2
Figure 3~4
AI summary
The present invention provides a compound of a formula (I): wherein the variables are defined herein; to a process for preparing such a compound; and to the use of such a compound in the treatment of a chemokine (such as CCR3) mediated disease state.